Prosecution Insights
Last updated: April 19, 2026
Application No. 17/605,889

Systems and Methods for Targeting Dirofilaria immitis and Dirofilaria repens

Non-Final OA §103
Filed
Oct 22, 2021
Examiner
SITTON, JEHANNE SOUAYA
Art Unit
1682
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Smith College
OA Round
3 (Non-Final)
53%
Grant Probability
Moderate
3-4
OA Rounds
3y 11m
To Grant
99%
With Interview

Examiner Intelligence

Grants 53% of resolved cases
53%
Career Allow Rate
348 granted / 660 resolved
-7.3% vs TC avg
Strong +48% interview lift
Without
With
+47.6%
Interview Lift
resolved cases with interview
Typical timeline
3y 11m
Avg Prosecution
51 currently pending
Career history
711
Total Applications
across all art units

Statute-Specific Performance

§101
24.7%
-15.3% vs TC avg
§103
22.6%
-17.4% vs TC avg
§102
14.5%
-25.5% vs TC avg
§112
29.2%
-10.8% vs TC avg
Black line = Tech Center average estimate • Based on career data from 660 resolved cases

Office Action

§103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Continued Examination Under 37 CFR 1.114 A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 11/17/2025 has been entered. Status of Claims Currently, claims 28, 31-35, 37, and 41-49 are pending in the instant application. All the amendments and arguments have been thoroughly reviewed but are deemed insufficient to place this application in condition for allowance. The following rejections are either newly applied, as necessitated by amendment, or are reiterated. They constitute the complete set being presently applied to the instant Application. Response to Applicant's arguments follow. This action is Non-FINAL. The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action. Any rejection not reiterated is hereby withdrawn in view of the amendments to the claims. Claim Rejections - 35 USC § 103 Claims 28, 32, 34, 43, and 47 are rejected under 35 U.S.C. 103 as being unpatentable over Fodor (Fodor et al; US 6,582,908) in view of Ahern (Ahern, Holly, The Scientist, vol 9, 1995, pages 1-5). Fodor teaches an array of all possible 10 mer nucleic acid sequences (see claims) which necessarily encompasses a DNA that is complementary to SEQ ID NO: 1 or 2. It is noted that “a conjugation moiety” is defined as a chemical moiety attached to a nucleic acid molecule that facilitates binding the nucleic acid to a capture medium, which is necessarily taught by Fodor as the oligonucleotides are bound to an array. Although the claims have been amended to recite a capture medium and capture oligonucleotide component “consisting of” a set of capture oligonucleotides, the set “consisting of” a first capture probe and a second capture probe, the kit itself recites the term “comprising” such that additional components are within the scope of the claim. Additionally, the section of the array taught by Fodor that contains two probes “complementary” to the recited SEQ ID NO: can be considered a “set” and the section of the array they attach to can be considered a capture medium. Although Fodor does not teach a kit comprising the array with written instructions, Ahern teaches kits comprising instructions, Ahern teaches that packaging reagents in kit format save practitioners time. Therefore it would have been prima facie obvious to one having ordinary skill in the art prior to the effective filing date to have provided the array taught by Fodor in kit format as taught by Ahern to save practitioners time. Conclusion The prior art made of record and not relied upon is considered pertinent to applicant's disclosure. US Patent 6,268,153 teaches labeled DNA oligonucleotides that hybridize to repeat sequences of Dirofilaria immitus, however the oligonucleotides are not complementary to or capable of hybridizing to SEQ ID NO: 1 or 2. No claims are allowed. Claims 31, 33, 35, 37, 41-42, 44-46, and 48-49 are objected to for being dependent on a rejected claim. Any inquiry concerning this communication or earlier communications from the examiner should be directed to examiner Jehanne Sitton whose telephone number is (571) 272-0752. The examiner is a hoteling examiner and can normally be reached Mondays-Fridays from 8:00 AM to 2:00 PM Eastern Time Zone. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Winston Shen, can be reached on (571) 272-3157. The fax phone number for organization where this application or proceeding is assigned is (571) 273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /JEHANNE S SITTON/Primary Examiner, Art Unit 1682
Read full office action

Prosecution Timeline

Oct 22, 2021
Application Filed
Nov 30, 2024
Non-Final Rejection — §103
Mar 04, 2025
Response Filed
Jun 14, 2025
Final Rejection — §103
Sep 17, 2025
Response after Non-Final Action
Nov 17, 2025
Request for Continued Examination
Nov 18, 2025
Response after Non-Final Action
Mar 07, 2026
Non-Final Rejection — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12595469
TREATMENT OF RETINITIS PIGMENTOSA USING IMPROVED ENGINEERED MEGANUCLEASES
2y 5m to grant Granted Apr 07, 2026
Patent 12577569
APTAMERS FOR THE REVERSIBLE INHIBITION OF DNA POLYMERASES
2y 5m to grant Granted Mar 17, 2026
Patent 12571050
METHOD OF PREDICTING RESPONSE TO THERAPY BY ASSESSING TUMOR GENETIC HETEROGENEITY
2y 5m to grant Granted Mar 10, 2026
Patent 12571030
LAMC2-NR6A1 Splicing Variant and Translation Product Thereof
2y 5m to grant Granted Mar 10, 2026
Patent 12545948
IDENTIFICATION OF NOVEL LOCI IN ASTHMA AND METHODS OF USE THEREOF FOR THE DIAGNOSIS AND TREATMENT OF ASTHMA
2y 5m to grant Granted Feb 10, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

3-4
Expected OA Rounds
53%
Grant Probability
99%
With Interview (+47.6%)
3y 11m
Median Time to Grant
High
PTA Risk
Based on 660 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month